Chairman and Chief Executive Officer
Mr. McKee brings more than 20 years of biotechnology, life sciences management and leadership and venture investment experience to the company. Before joining Tryp, he founded Torrent Ventures, an early stage digital health and medical technology venture fund, and served as chief executive officer of CONNECT, the largest Southern California start-up accelerator creating and scaling innovative life sciences and technology companies. Prior to CONNECT he was chairman, president and chief executive officer publicly traded Nventa Biopharmacueticals which successfully merged with Akela Pharma. Additionally, he has held senior management roles at Genzyme Corporation, which was acquired by Sanofi for $22 billion. Mr. McKee has lived and worked in Tokyo, Japan for seven years managing a $550M investment portfolio at the Mizuho Group and as an investment banker with UBS. He was also senior advisor to the Former Minister of Foreign Affairs of Japan. Additionally, Mr. McKee lived and worked in Singapore for 2 years, managing Genzyme's business units in South East Asia and mainland China.
Mr. McKee earned a B.A. in Economics from the University of Washington, a M.A. in International Studies from The Joseph H. Lauder Institute and an M.B.A from the Wharton School, at the University of Pennsylvania. He has been a member of Young President's Organization (YPO) since 2006.
James Gilligan, Ph.D
President & Chief Scientific Officer
Dr. Gilligan has over 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs, and manufacturing. Prior to joining Tryp Therapeutics, Dr. Gilligan was a Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm providing regulatory and product development support to pharmaceutical and biotech companies. Dr. Gilligan was a co-founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones, as well as oral and nasal delivery technologies for peptide based therapeutics. Dr. Gilligan was also a Co-Founder and the Chief Scientific Officer of Tarsa Therapeutics.
Dr. Gilligan received a PhD from University of Connecticut and a Masters in International Business from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.
Chief Financial Officer
Mr. Hayes has been active in the life science industry for more than 20 years with experience in technology transfer, venture capital, and finance. He started his career doing business development for Dow Chemical with responsibility for pharmaceutical customers including Lilly and AbbVie. He spent more than a decade doing venture capital investing while supporting a wide range of companies as a Director and advisor. Mr. Hayes has deep experience with corporate finance and capital formation activities as well as extensive relationships throughout the life science industry.
Mr. Hayes earned a B.S. in Chemical Engineering from Brigham Young University and an M.B.A. from the UCLA Anderson School of Management.
Chief Operating Officer
Mr. D’Orazio has extensive experience leading the development and commercialization of vaccines, drugs, radiopharmaceuticals, and biologics. His leadership experience has been in commercial planning, business development, marketing and partnership management roles. Mr. D’Orazio was formerly the CEO of ImmunoPrecise Antibodies (TSXV:IPA) where he led the transition from a private company to a public company. He co-founded and led Superna Life Sciences as CEO, a specialty-pharma company focusing on niche drugs for cancer patients in Canada where he successfully in-licensed two products and succeeded in getting Health Canada approval for both drugs in head & neck cancer and prostate cancer respectively. He has commercialization experience at all stages of drug development primarily in oncology, rare diseases and ophthalmology products respectively. He held roles in business development doing both in-licensing and out-licensing as well as managing partnerships between companies and sitting on their joint development teams. At QLT he was responsible for managing their $500M/year commercial partnership with Novartis. Prior to working for QLT, Mr. D’Orazio was at Pfizer (Pharmacia U.S.A.) and managed a $250M/year portfolio that included human growth hormone where he was involved in the strategic planning for label expansion for the Prader-Willi syndrome indication.
Mr. D’Orazio has an M.B.A from Vanderbilt University with an emphasis in both Finance and Marketing and a B.Sc. in chemistry from Loyola University of Chicago.
Vice President, Manufacturing
Mr. Norder has over 30 years of experience in the pharmaceutical and biotech industry. He has led chemistry aspects of early stage R&D, preclinical and clinical development programs for such products as naproxen, mycophenylate mofetil, gancyclovir, ketorolac tromethamine, nafarelin acetate, palonosetron, and topical corticosteroids. He has also been responsible for top line revenues for contract research and manufacturing, cheminformatic and bioinformatic software and associated services. Most recently, Mr. Norder has turned to the application of these set of skills to innovation and manufacturing in the nutraceuticals and natural supplements world. He has developed novel technologies to increase transdermal delivery of BCS Class II molecules, oral formulations to increase bioavailability and inhalation formulations for increased safety and efficacy. He has also developed novel methods of extraction, isolation and characterization of desirable phytochemicals.
Mr. Norder earned his B.S in chemistry from the University of Illinois, a certificate in Network Software Technology Management from University of California, Santa Cruz. Mr. Norder is a member of the American Chemical Society (ACS), the American Association of Pharmaceutical Scientists (AAPS) and the International Society of Pharmaceutical Engineers (IPSE).
Peter Guzzo, Ph.D
Vice President, Drug Development
Dr. Guzzo has devoted his entire 25-year professional career to innovative therapeutics for poorly treated diseases. He has been involved in drug discovery, clinical research, and executive level roles. He has led cross-functional teams that delivered eleven innovative drugs into clinical development. His experience collaborating with pharma, biotech, academic institutions and contract research organizations will help us execute and push forward our drug development pipeline. Dr. Guzzo has broad knowledge in several therapeutic indications including central nervous system diseases, metabolic disorders and oncology, intellectual property creation, and building entrepreneurial teams. He is an inventor on 43 patents, co-authored 47 scientific publications, and presented 28 invited lectures.
Director, Investor Relations
Ms. Willis joined Try Therapeutics as Director, Investor Relations in 2021. Ms. Willis brings extensive experience managing investor relations activities for life science companies to her role. She previously served as an Analyst at Solebury Trout, a leading investor relations and corporate communications firm specializing in life sciences. While at the firm, Ms. Willis supported nearly 20 publicly traded life science companies with their investor relations and communications activities.
Ms. Willis earned a B.A. in Environmental Science and Policy at Florida State University.